PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study is conducted to evaluate the benefit of adding palbociclib in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer patients, regardless of menopausal status, treated with tamoxifen (with or without goserelin) versus tamoxifen alone (with or without goserelin).
Epistemonikos ID: 09a5e964c6dbb28a6dd4b05a0ddbc32901258eb7
First added on: May 21, 2024